Serum amyloid A as an aid in diagnosing sepsis in equine neonates
The septic foals had a median SAA concentration that was significantly greater than that for foals in the sick non-septic and healthy groups
Background: Sepsis is a significant cause of morbidity and mortality in neonatal foals, especially during the first seven days of life. Diagnosing sepsis in neonatal foals can be challenging because initial clinical signs are often ambiguous and non-specific.
Objectives: To determine if the major acute phase protein serum amyloid A (SAA) as measured by a point-of-care SAA testing device can be used as an evidence-based biomarker of sepsis.
Study design: Retrospective cohort.
Methods: Clinical diagnosis of sepsis based on positive bacterial blood culture or a positive sepsis score was obtained and compared to SAA values in a population of neonatal foals on a breeding farm and referral hospital during four consecutive foaling seasons. A rapid, point-of-care blood test was used to measure SAA concentrations in neonatal foals <36 hours old that were clinically diagnosed as healthy, sick non-septic, or septic.
Results: The septic foals (n= 35) had a median SAA concentration (114 µg/mL) that was significantly greater (P<0.05) than that for foals in the sick non-septic (n=117, 1.5 µg/mL) and healthy (n=245, 0 µg/mL) groups. At a diagnostic threshold of 100 µg/mL, the SAA test had a sensitivity of 52.9% (95% CI 36.5 -68.9), specificity of 97.5% (95% CI 95.0-99.0), positive predictive value of 75.0% (95% CI 56.2-87.5), negative predictive value of 93.7% (95% CI 91.2-95.5), and a test accuracy of 92.1% (95% CI 88.2-95.0).
Conclusions: The results of this study indicate that SAA is a useful aid in the diagnosis of sepsis in the neonatal foal.
“Serum amyloid A as an aid in diagnosing sepsis in equine neonates” Bonnie Barr, et al. Equine Vet J. 2021 Nov 13. doi: 10.1111/evj.13540.
Comments
Related Articles
Copyright © 2025 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment